A phase II, randomized, double-blind, placebo-controlled, 24-week dose finding study to evaluate the efficacy and safety of 20mg, 40mg and 80mg of MCC-257 [coleneuramide] in patients with mild to moderate diabetic polyneuropathy
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2007
At a glance
- Drugs Coleneuramide (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Mitsubishi Pharma Corporation
- 27 Dec 2007 Status changed from in progress to completed.
- 27 Oct 2006 New trial record.